-
HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients: (Trends in Molecular Medicine, 30:3 p:278–294, 2024). Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-19 Chiara Mozzetta, Vittorio Sartorelli, Christian Steinkuhler, Pier Lorenzo Puri
Abstract not available
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-17 Sarah J. Annesley, Serkan Kir, Yang Liu, Alankrita Rani
Abstract not available
-
Harnessing gastrointestinal organoids for cancer therapy Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-13 Gunter Maubach, Michael Naumann
Gastrointestinal organoids have emerged as a model system that authentically recapitulates the in vivo situation. Despite biomedical and technical challenges, self-assembled 3D structures derived from pluripotent stem cells or healthy and diseased tissues have proved to be invaluable tools for cancer drug discovery, disease modeling, and studying infection with carcinogenic pathogens.
-
Exploiting pancreatic cancer metabolism: challenges and opportunities Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-10 Maria Chiara De Santis, B. Bockorny, E. Hirsch, P. Cappello, M. Martini
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive form of pancreatic cancer, known for its challenging diagnosis and limited treatment options. The focus on metabolic reprogramming as a key factor in tumor initiation, progression, and therapy resistance has gained prominence. In this review we focus on the impact of metabolic changes on the interplay among stromal, immune, and tumor cells
-
-
Eating disorders – enemies of the body and mind Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-10 Aliki Perdikari
Abstract not available
-
Subscription and Copyright Information Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-10
Abstract not available
-
SOX17: escape route from immune destruction in early CRC Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-09 Kostas A. Papavassiliou, Christos Adamopoulos, Athanasios G. Papavassiliou
In a recent report in Nature, Goto et al. reveal a novel immune-evasion mechanism adopted by early colorectal cancer (CRC) cells that is based on the transcription factor sex determining region Y (SRY)-box transcription factor 17 (SOX17). Leveraging colorectal adenoma and cancer models to perform comprehensive transcriptomic/chromatin analyses, this work shows that SOX17 generates immune-silent leucine-rich
-
Targeting connexins: possible game changer in managing neuropathic pain? Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-08 Yixun Su, Alexei Verkhratsky, Chenju Yi
Neuropathic pain is a chronic debilitating condition caused by nerve injury or a variety of diseases. At the core of neuropathic pain lies the aberrant neuronal excitability in the peripheral and/or central nervous system (PNS and CNS). Enhanced connexin expression and abnormal activation of connexin-assembled gap junctional channels are prominent in neuropathic pain along with reactive gliosis, contributing
-
Molecular mechanisms in the pathogenesis of dengue infections Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-05 Gathsaurie Neelika Malavige, Graham S. Ogg
Dengue is the most rapidly emerging climate-sensitive infection, and morbidity/mortality and disease incidence are rising markedly, leading to healthcare systems being overwhelmed. There are currently no specific treatments for dengue or prognostic markers to identify those who will progress to severe disease. Owing to an increase in the burden of illness and a change in epidemiology, many patients
-
Cell-free DNA methylation in the clinical management of lung cancer Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-05 Mark Ezegbogu, Emma Wilkinson, Glen Reid, Euan J. Rodger, Ben Brockway, Takiwai Russell-Camp, Rajiv Kumar, Aniruddha Chatterjee
The clinical use of cell-free DNA (cfDNA) methylation in managing lung cancer depends on its ability to differentiate between malignant and healthy cells, assign methylation changes to specific tissue sources, and elucidate opportunities for targeted therapy. From a technical standpoint, cfDNA methylation analysis is primed as a potential clinical tool for lung cancer screening, early diagnosis, prognostication
-
Pelizaeus–Merzbacher disease: on the cusp of myelin medicine Trends Mol. Med. (IF 13.6) Pub Date : 2024-04-05 Matthew S. Elitt, Paul J. Tesar
Pelizaeus–Merzbacher disease (PMD) is caused by mutations in the proteolipid protein 1 (PLP1) gene encoding proteolipid protein (PLP). As a major component of myelin, mutated PLP causes progressive neurodegeneration and eventually death due to severe white matter deficits. Medical care has long been limited to symptomatic treatments, but first-in-class PMD therapies with novel mechanisms now stand
-
Redefining the biological and pathophysiological role of dimethylarginine dimethylaminohydrolase 2 Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-29 Pramod C. Nair, Arduino A. Mangoni, Roman N. Rodionov
The enzyme dimethylarginine dimethylaminohydrolase (DDAH) 1 metabolizes asymmetric dimethylarginine (ADMA), a critical endogenous cardiovascular risk factor. In the past two decades, there has been significant controversy about whether DDAH2, the other DDAH isoform, is also able to directly metabolize ADMA. There has been evidence that DDAH2 regulates several critical processes involved in cardiovascular
-
Endoscopic duodenal mucosa ablation: the future of diabetes treatment? Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-29 Giovanni Musso, Maurizio Cassader, Roberto Gambino
Duodenal mucosa ablation (DMA) is a novel approach to treat diabetes, consisting of endoscopic ablation of dysfunctional diabetic duodenal mucosa, which, following the healing response, is replaced by normally functioning mucosa. Two techniques, duodenal mucosal resurfacing (DMR) and recellularization via electroporation therapy (ReCET), recently showed promise in type 2 diabetes mellitus (T2DM) patients
-
SnoRNAs in cardiovascular development, function, and disease Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-23 Alzbeta Chabronova, Terri L. Holmes, Duc M. Hoang, Chris Denning, Victoria James, James G.W. Smith, Mandy J. Peffers
Small nucleolar RNAs (snoRNAs) are emerging as important regulators of cardiovascular (patho)biology. Several roles of snoRNAs have recently been identified in heart development and congenital heart diseases, as well as their dynamic regulation in hypertrophic and dilated cardiomyopathies, coronary heart disease (CHD), myocardial infarction (MI), cardiac fibrosis, and heart failure. Furthermore, reports
-
Emerging roles of MRG15 in liver metabolic diseases Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-22 Cheng Tian, Xiaosong Gu, Chunping Jiang, Qiurong Ding
MORF4 (mortality factor on chromosome 4)-related gene 15 (MRG15) is a chromodomain protein that exists in various multiprotein complexes involved in transcription, DNA repair, and development. Here we summarize the recent advances involving MRG15 in modulating liver metabolism, both through its chromatin-binding capability and independently of it, highlighting MRG15 as a potential therapeutic target
-
New media facilitate adolescents’ body dissatisfaction and eating disorders in Mainland China Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-22 Jue Chen, Sufang Peng, Yaohui Wei
New media play a significant role in adolescents’ body dissatisfaction and eating disorders in Mainland China, through shaping social standards, peers, and family dynamics. How to mitigate their adverse effects on adolescents, reduce body dissatisfaction, and prevent eating disorders is a significant social issue that demands serious consideration.
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-21 Fernando Fernandez-Aranda, Jue Chen, Claire Foldi, Hubertus Himmerich, Janet Treasure, Jiayi Xu
Abstract not available
-
Amphiphysin-2 (BIN1) functions and defects in cardiac and skeletal muscle Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-20 Quentin Giraud, Jocelyn Laporte
Amphiphysin-2 is a ubiquitously expressed protein also known as bridging integrator 1 (BIN1), playing a critical role in membrane remodeling, trafficking, and cytoskeleton dynamics in a wide range of tissues. Mutations in the gene encoding BIN1 cause centronuclear myopathies (CNM), and recent evidence has implicated BIN1 in heart failure, underlining its crucial role in both skeletal and cardiac muscle
-
The current sociocultural background of eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-18 Nikolett Bogár, Bea Pászthy, Ferenc Túry
Eating disorders (EDs) are complex phenomena that are partly influenced by sociocultural factors. The thin body ideal of Western civilization, disseminated by mass media and reinforced by the fashion industry, plays a significant role. In this cultural environment, the social perception of the human body has undergone a change.
-
Established and emerging treatments for eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-18 Callum Bryson, Daire Douglas, Ulrike Schmidt
Eating disorders (EDs) are common mental health conditions that carry exceedingly high morbidity and mortality rates. Evidence-based treatment options include a range of psychotherapies and some, mainly adjunctive, pharmacological interventions. However, around 20–30% of people fail to respond to the best available treatments and develop a persistent treatment-refractory illness. Novel treatments for
-
Eating disorders and obesity: bridging clinical, neurobiological, and therapeutic perspectives Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-14 Lucia Camacho-Barcia, Katrin Elisabeth Giel, Susana Jiménez-Murcia, Julio Álvarez Pitti, Nadia Micali, Ignacio Lucas, Romina Miranda-Olivos, Lucero Munguia, Manuel Tena-Sempere, Stephan Zipfel, Fernando Fernández-Aranda
Eating disorders (EDs) and obesity are complex health conditions sharing various risk and maintenance factors, intensified in cases of comorbidity. This review explores the similarities and connections between these conditions, examining different facets from a multidisciplinary perspective, among them comorbidities, metabolic and psychological factors, neurobiological aspects, and management and therapy
-
mRNA vaccine platforms to prevent bacterial infections Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-13 Carson Bergstrom, Nicholas O. Fischer, Jessica Z. Kubicek-Sutherland, Zachary R. Stromberg
Bacterial infections are an urgent public health priority. The application of mRNA vaccine technology to prevent bacterial infections is a promising therapeutic strategy undergoing active development. This article discusses recent advances and limitations of mRNA vaccines to prevent bacterial diseases and provides perspectives on future research directions.
-
iPSC-derived models for anorexia nervosa research Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-12 Gilles Maussion, Cecilia Rocha, Nicolas Ramoz
Anorexia nervosa (AN) is a complex neuropsychiatric disorder with genetic and epigenetic components that results in reduced food intake combined with alterations in the reward-processing network. While studies of patient cohorts and mouse models have uncovered genes and epigenetic changes associated with the disease, neuronal networks and brain areas preferentially activated and metabolic changes associated
-
The body is not just impacted by eating disorders – biology drives them Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-09 James Downs
Current theoretical understandings of eating disorders often characterize physiological symptoms as secondary consequences driven by core psychological difficulties. This article emphasizes the need to learn from the lived experiences of patients which indicate how biological factors can be central in the development, maintenance, and ultimately the treatment of eating disorders.
-
Clinical crusade: zosurabalpin's charge against antibiotic resistance Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-07 Wancai Que, Zixin Deng, Jiangtao Gao
In a recent report, Zampaloni et al. describe a novel tethered macrocyclic peptide (MCP) antibiotic, zosurabalpin, that disrupts the essential function of the LptB2FGC complex in Gram-negative bacteria and demonstrates efficacy against carbapenem-resistant Acinetobacter baumannii (CRAB). Its preclinical success suggests a substantial shift in treating antibiotic resistance, pending clinical trials
-
Epigenetic regulation of tumor-immune symbiosis in glioma Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-07 Yang Liu, Heba Ali, Fatima Khan, Lizhi Pang, Peiwen Chen
Glioma is a type of aggressive and incurable brain tumor. Patients with glioma are highly resistant to all types of therapies, including immunotherapies. Epigenetic reprogramming is a key molecular hallmark in tumors across cancer types, including glioma. Mounting evidence highlights a pivotal role of epigenetic regulation in shaping tumor biology and therapeutic responses through mechanisms involving
-
Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-04 Sarah J. Annesley, Daniel Missailidis, Benjamin Heng, Elisha K. Josev, Christopher W. Armstrong
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic illness often triggered by an initiating acute event, mainly viral infections. The transition from acute to chronic disease remains unknown, but interest in this phenomenon has escalated since the COVID-19 pandemic and the post-COVID-19 illness, termed ‘long COVID’ (LC). Both ME/CFS and LC share many clinical similarities
-
Ectodysplasin A2 receptor signaling in skeletal muscle pathophysiology Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-04 Sevgi Döndü Özen, Serkan Kir
Skeletal muscle is essential in generating mechanical force and regulating energy metabolism and body temperature. Pathologies associated with muscle tissue often lead to impaired physical activity and imbalanced metabolism. Recently, ectodysplasin A2 receptor (EDA2R) signaling has been shown to promote muscle loss and glucose intolerance. Upregulated EDA2R expression in muscle tissue was associated
-
Dissecting the biology of feeding and eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-01 Laura M. Huckins, Kristen Brennand, Cynthia M. Bulik
Feeding and eating disorders (FEDs) are heterogenous and characterized by varying patterns of dysregulated eating and weight. Genome-wide association studies (GWASs) are clarifying their underlying biology and their genetic relationship to other psychiatric and metabolic/anthropometric traits. Genetic research on anorexia nervosa (AN) has identified eight significant loci and uncovered genetic correlations
-
HDL and SARS CoV-2: emerging theragnostic implications Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-01 Alankrita Rani, Julia T. Stadler, Gunther Marsche
High-density lipoproteins (HDLs) are complex particles with multiple functions. They are thought to have evolved as part of the body’s innate defense system against infection. Recent research suggests that HDL levels influence susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the severity of associated complications, making it a promising target for therapeutic
-
HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-26 Chiara Mozzetta, Vittorio Sartorelli, Pier Lorenzo Puri
Earlier evidence that targeting the balance between histone acetyltransferases (HATs) and deacetylases (HDACs), through exposure to HDAC inhibitors (HDACis), could enhance skeletal myogenesis, prompted interest in using HDACis to promote muscle regeneration. Further identification of constitutive HDAC activation in dystrophin-deficient muscles, caused by dysregulated nitric oxide (NO) signaling, provided
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-23 Jeremy P. Burton, Rikke Hahn Kofoed, Ruslan Rust
-
There is nothing as inconsistent as the OSFED diagnostic criteria Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-22 Isabel Krug, An Binh Dang, Elizabeth K. Hughes
Atypical anorexia nervosa (AAN), purging disorder (PD), night eating syndrome (NES), and subthreshold bulimia nervosa and binge-eating disorder (Sub-BN/BED) are the five categories that comprise the ‘Other Specified Feeding or Eating Disorder’ (OSFED) category in the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). In this review, we examine problems with the diagnostic criteria that
-
-
-
Anorexia nervosa: diagnostic, therapeutic, and risk biomarkers in clinical practice Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-08 Hubertus Himmerich, Janet Treasure
In anorexia nervosa (AN), measurable biological parameters can inform the process of treating patients. Such biomarkers include established laboratory parameters as well as a range of potential future biomarkers, including genetic, metabolomic, microbiomic, endocrine, immunological, hematological, electrophysiological, and neuroimaging parameters. In this opinion article we discuss how these biomarkers
-
Hyaluronan deposition during COVID-19 – helpful or harmful? Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-07 Duncan Hart, William A. Petri
Hyaluronan (HA), an extracellular matrix polysaccharide, is increased in the lungs during COVID-19 and correlates with severity. HA acts as an immune mediator that aids cell trafficking and intracellular signaling, but its role in COVID-19 is debated. Although HA is implicated in pulmonary viral disease pathogenesis, some studies suggest a potential protective function in COVID-19.
-
Immune cell-derived signals governing epithelial phenotypes in homeostasis and inflammation Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-05 Annika Hausmann, Casper Steenholdt, Ole H. Nielsen, Kim B. Jensen
The intestinal epithelium fulfills important physiological functions and forms a physical barrier to the intestinal lumen. Barrier function is regulated by several pathways, and its impairment contributes to the pathogenesis of inflammatory bowel disease (IBD), a chronic inflammatory condition affecting more than seven million people worldwide. Current treatment options specifically target inflammatory
-
Organ-specific aging in the plasma proteome predicts disease Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-31 Michael R. Duggan, Keenan A. Walker
In their recent Nature paper, Oh et al. use 4979 plasma proteins collected across multiple cohorts, publicly available gene expression data, and machine learning models to identify 11 organ-specific aging scores that are linked to organ-specific disease and mortality risk, including heart failure, cognitive decline, and Alzheimer’s disease.
-
TIM-3 inhibitors: a promising strategy for tumor immunotherapy Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-31 Lu Lu, Liufu Deng
recently reported a systematic screening of small-molecule compounds targeting the FG-CC' cleft of T cell immunoglobulin and mucin-containing molecule 3 (TIM-3). They identified a functional Tim-3 inhibitor, ML-T7, that, as a single agent or in combination with anti-PD-1, demonstrated strong antitumor activity in preclinical mouse tumor models, supporting its potential for further clinical translation
-
Resistance exercise for anxiety and depression: efficacy and plausible mechanisms Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-30 Matthew P. Herring, Jacob D. Meyer
Anxiety and depressive symptoms and disorders are prevalent and poorly treated. The salutary benefits of resistance exercise training (RET), a potential alternative therapy, are well established, but mental health effects are understudied. This forum article summarizes the most rigorous evidence regarding efficacy of resistance exercise and provides a primer for putative psychobiological mechanisms
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-25 Pedro Antas, Abigail Cleveland, Paolo Contessotto, Raffael Schaffrath
Abstract not available
-
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-24 Federica Pilotto, Deepika M. Chellapandi, Hélène Puccio
Friedreich ataxia (FA) is an inherited autosomal recessive neurodegenerative disease (NDD) characterized primarily by progressive sensory and spinocerebellar ataxia associated with hypertrophic cardiomyopathy. FA is due to an intronic GAA repeat expansion within the frataxin gene (FXN) leading to reduced levels of frataxin (FXN) which causes mitochondrial dysfunction, production of reactive oxygen
-
Beneath the radar: immune-evasive cell sources for stroke therapy Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-25 Beatriz Achón Buil, Nora H. Rentsch, Rebecca Z. Weber, Chiara Rickenbach, Stefanie J. Halliday, Akitsu Hotta, Christian Tackenberg, Ruslan Rust
Stem cell therapy is an emerging treatment paradigm for stroke patients with remaining neurological deficits. While allogeneic cell transplants overcome the manufacturing constraints of autologous grafts, they can be rejected by the recipient’s immune system, which identifies foreign cells through the human leukocyte antigen (HLA) system. The heterogeneity of HLA molecules in the human population would
-
Focused ultrasound gene delivery for the treatment of neurological disorders Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-11 Rikke Hahn Kofoed, Isabelle Aubert
The transformative potential of gene therapy has been demonstrated in humans. However, there is an unmet need for non-invasive targeted gene delivery and regulation in the treatment of brain disorders. Transcranial focused ultrasound (FUS) has gained tremendous momentum to address these challenges. FUS non-invasively modulates brain cells and their environment, and is a powerful tool to facilitate
-
The sense of antisense therapies in ALS Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-11 Sien H. Van Daele, Pegah Masrori, Philip Van Damme, Ludo Van Den Bosch
Treatment of patients with amyotrophic lateral sclerosis (ALS) has entered a new era now that encouraging results about antisense oligonucleotides (ASOs) are becoming available and a first ASO therapy for ALS has been approved by the FDA. Moreover, there is hope not only that ALS can be stopped but also that symptoms can be reversed. Until now, degrading ASOs seemed to be successful mostly for rarer
-
-
Let science take you around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-10 Aliki Perdikari
Abstract not available
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-10 Navika Gangrade, Cecilia Hidalgo, Thirumala-Devi Kanneganti, Gwendal Lazennec
Abstract not available
-
Subscription and Copyright Information Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-10
Abstract not available
-
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-08 Catherine M. Andary, Kait F. Al, John A. Chmiel, Shaeley Gibbons, Brendan A. Daisley, Seema Nair Parvathy, Saman Maleki Vareki, Dawn M.E. Bowdish, Michael S. Silverman, Jeremy P. Burton
Fecal microbiota transplantation (FMT) has emerged as an alternative or adjunct experimental therapy for microbiome-associated diseases following its success in the treatment of recurrent infections (rCDIs). However, the mechanisms of action involved remain relatively unknown. The term ‘dysbiosis’ has been used to describe microbial imbalances in relation to disease, but this traditional definition
-
Immune system perturbations in patients with long COVID Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-04 Lucie Rodriguez, Petter Brodin
report multimodal analyses of immune cells, proteins, and physiological parameters in patients with long COVID (LC). At the group level, LC subjects exhibited elevated antibody responses to SARS-CoV-2, but also to herpes viruses, pointing to a general suppression of viral control mechanisms in LC.
-
Glycosylation of blood cells during the onset and progression of atherosclerosis and myocardial infarction Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-22 Federico Ferro, Renza Spelat, Abhay Pandit, José L. Martin-Ventura, Gabriel A. Rabinovich, Paolo Contessotto
Protein glycosylation controls cell–cell and cell–extracellular matrix (ECM) communication in immune, vascular, and inflammatory processes, underlining the critical role of this process in the identification of disease biomarkers and the design of novel therapies. Emerging evidence highlights the critical role of blood cell glycosylation in the pathophysiology of atherosclerosis (ATH) and myocardial
-
From disparities to equity: striving for more in our treatments for feeding and eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-21 Rachel W. Goode, Salomé Adelia Wilfred, Mae Lynn Reyes-Rodríguez
Adopting a framework of equity is urgently needed to reduce disparities persistent in feeding and eating disorder (FED) treatment models. This framework must emphasize the exchange of knowledge between relevant stakeholders and implementation strategies to impact practice and embrace a systemic change in the FED field.
-
FBXL4 mutation-caused mitochondrial DNA depletion syndrome is driven by BNIP3/BNIP3L-dependent excessive mitophagy Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-19 Kun Gao, Xiayun Xu, Chenji Wang
Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is an autosomal recessive disorder arising from biallelic F-box and leucine-rich repeat (LRR) protein 4 (FBXL4) gene mutations. Recent advances have shown that excessive BCL2 interacting protein 3 (BNIP3)/ BCL2 interacting protein 3 like (BNIP3L)-dependent mitophagy underlies the molecular pathogenesis of MTDPS13. Here, we
-
Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-19 Trevor Steward
The neurobiology of eating disorders [EDs; anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)] remains poorly understood. Here, I describe how neuroimaging, accompanied by peripheral endocrine measures, can provide insights into the neurobiological drivers of eating disorders. Orexins/hypocretins, glucagon-like peptide-1 receptor (GLP1R) agonists, and psilocybin are highlighted
-
Diphthamide – a conserved modification of eEF2 with clinical relevance Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-13 Raffael Schaffrath, Ulrich Brinkmann
Diphthamide, a complex modification on eukaryotic translation elongation factor 2 (eEF2), assures reading-frame fidelity during translation. Diphthamide and enzymes for its synthesis are conserved in eukaryotes and archaea. Originally identified as target for diphtheria toxin (DT) in humans, its clinical relevance now proves to be broader than the link to pathogenic bacteria. Diphthamide synthesis
-
TIM-3 blockade: immune and targeted therapy in DIPG Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-12 Yan Hu, Peishan Hu, Xiaozhong Peng
Diffuse intrinsic pontine glioma (DIPG) remains intractable to conventional treatments. While targeted therapy and immuno-oncology advances offer hope, few strategies show promising results. In a recent article in Cancer Cell, Ausejo-Mauleon et al. introduce TIM-3 blockade as a potential breakthrough for DIPG treatment by targeting cancer cells and regulating the immune microenvironment simultaneously
-
Taking better advantage of the activity-based anorexia model Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-15 Claire J. Foldi
The lack of specific treatments for anorexia nervosa (AN) is partly driven by an inadequate understanding of the neurobiological drivers of the condition. The activity-based anorexia (ABA) model recapitulates key characteristics of AN in rats and mice, and can be used to understand factors that predispose, maintain, and rescue anorectic behaviour. With the rapidly evolving suite of technologies to